← back to search

Camille C. Gunderson

University of Oklahoma Health Sciences Center · US
Area of research
Reproductive Medicine · Obstetrics and Gynecology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy, and Radiomics and Machine Learning in Medical Imaging.
h-index
26
citations
2,577
works
93
NIH funding
primary concept
Medicine
email

Recent publications

An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial
Gynecologic Oncology 2021cited by 29position: middledoi
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
Journal of Clinical Oncology 2020cited by 346position: middledoi
A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
Gynecologic Oncology 2019cited by 103position: middledoi
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer
Gynecologic Oncology 2019cited by 18position: lastdoi
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis
Gynecologic Oncology 2016cited by 100position: middledoi
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort
Gynecologic Oncology 2016cited by 43position: middledoi
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary
International Journal of Gynecological Cancer 2015cited by 40position: middledoi
Vaginal Cancer
Journal of Lower Genital Tract Disease 2013cited by 16position: firstdoi
Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic review
Gynecologic Oncology 2012cited by 463position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Kathleen N. Moore · Oklahoma City University5 papers (2013–2019)Britt Erickson · University of Alabama at Birmingham3 papers (2013–2016)Charles A. Leath · St. Vincent's Birmingham2 papers (2015–2016) · 2 papers (2015–2016)Jennifer J. Mueller · Memorial Sloan Kettering Cancer Center2 papers (2015–2016)Rebecca C. Arend · University of South Carolina2 papers (2019–2021)Mario M. Leitão · Memorial Sloan Kettering Cancer Center2 papers (2015–2016)Amanda N. Fader · University of Milano-Bicocca2 papers (2012–2016)Christine Walsh · University of Colorado Hospital2 papers (2015–2016)Robert A. Burger · Mersana Therapeutics (United States)2 papers (2019–2020)Oliver Zivanovic · Gynecologic Oncology Group2 papers (2016–2020) · 1 papers (2016–2016) · 1 papers (2016–2016)Cara Mathews · Mass General Brigham1 papers (2020–2020) · 1 papers (2019–2019) · 1 papers (2021–2021)Oladapo Yeku · Harvard University1 papers (2021–2021)Abby R. Rubenstein · University of Oklahoma Health Sciences Center1 papers (2019–2019)James Java · Roswell Park Comprehensive Cancer Center1 papers (2016–2016)Michael L. Pearl · Stony Brook School1 papers (2016–2016)